Cargando…

Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis

Background: In India, 50–65% of the population face difficulties in accessing medicines. The Health Impact Fund (HIF) is a novel proposal whereby pharmaceutical companies would be paid based on the measured global health impact of their drugs. We conducted a key stakeholder analysis to explore acces...

Descripción completa

Detalles Bibliográficos
Autores principales: McMullan, Patrick, Ajay, Vamadevan S., Srinivas, Ravi, Bhalla, Sandeep, Prabhakaran, Dorairaj, Banerjee, Amitava
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844053/
https://www.ncbi.nlm.nih.gov/pubmed/29495950
http://dx.doi.org/10.1080/16549716.2018.1434935
_version_ 1783305188836114432
author McMullan, Patrick
Ajay, Vamadevan S.
Srinivas, Ravi
Bhalla, Sandeep
Prabhakaran, Dorairaj
Banerjee, Amitava
author_facet McMullan, Patrick
Ajay, Vamadevan S.
Srinivas, Ravi
Bhalla, Sandeep
Prabhakaran, Dorairaj
Banerjee, Amitava
author_sort McMullan, Patrick
collection PubMed
description Background: In India, 50–65% of the population face difficulties in accessing medicines. The Health Impact Fund (HIF) is a novel proposal whereby pharmaceutical companies would be paid based on the measured global health impact of their drugs. We conducted a key stakeholder analysis to explore access to medicines in India, acceptability of the HIF and potential barriers and facilitators at policy level. Objectives: To conduct a stakeholder analysis of the HIF in India: to determine key stakeholder views regarding access to medicines in India; to evaluate acceptability of the HIF; and to assess potential barriers and facilitators to the HIF as a policy. Methods: In New Delhi, we conducted semi-structured interviews. There was purposive recruitment of participants with snowball sampling. Transcribed data were analysed using stakeholder analysis frameworks and directed content analysis. Results: Participation rate was 29% (14/49). 14 semi-structured interviews were conducted among stakeholders in New Delhi. All participants highlighted access to medicines as a problem in India. There were mixed views about the HIF in terms of relevance and scaleability. Stakeholders felt it should focus on diseases with limited or no market and potentially incorporate direct investment in research. Conclusions: First, access to medicines is perceived to be a major problem in India by all stakeholders, but affordability is just one factor. Second, stakeholders despite considerable support for the idea of the HIF, there are major concerns about scaleability, generalisability and impact on access to medicines. Third, the HIF and other novel drug-related health policies can afford to be more radical, e.g. working outside the existing intellectual property rights regime, targeting generic as well as branded drugs, or extending to research and development. Further innovations in access to medicines must involve country-specific key stakeholders in order to increase the likelihood of their success.
format Online
Article
Text
id pubmed-5844053
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-58440532018-03-13 Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis McMullan, Patrick Ajay, Vamadevan S. Srinivas, Ravi Bhalla, Sandeep Prabhakaran, Dorairaj Banerjee, Amitava Glob Health Action Original Article Background: In India, 50–65% of the population face difficulties in accessing medicines. The Health Impact Fund (HIF) is a novel proposal whereby pharmaceutical companies would be paid based on the measured global health impact of their drugs. We conducted a key stakeholder analysis to explore access to medicines in India, acceptability of the HIF and potential barriers and facilitators at policy level. Objectives: To conduct a stakeholder analysis of the HIF in India: to determine key stakeholder views regarding access to medicines in India; to evaluate acceptability of the HIF; and to assess potential barriers and facilitators to the HIF as a policy. Methods: In New Delhi, we conducted semi-structured interviews. There was purposive recruitment of participants with snowball sampling. Transcribed data were analysed using stakeholder analysis frameworks and directed content analysis. Results: Participation rate was 29% (14/49). 14 semi-structured interviews were conducted among stakeholders in New Delhi. All participants highlighted access to medicines as a problem in India. There were mixed views about the HIF in terms of relevance and scaleability. Stakeholders felt it should focus on diseases with limited or no market and potentially incorporate direct investment in research. Conclusions: First, access to medicines is perceived to be a major problem in India by all stakeholders, but affordability is just one factor. Second, stakeholders despite considerable support for the idea of the HIF, there are major concerns about scaleability, generalisability and impact on access to medicines. Third, the HIF and other novel drug-related health policies can afford to be more radical, e.g. working outside the existing intellectual property rights regime, targeting generic as well as branded drugs, or extending to research and development. Further innovations in access to medicines must involve country-specific key stakeholders in order to increase the likelihood of their success. Taylor & Francis 2018-03-02 /pmc/articles/PMC5844053/ /pubmed/29495950 http://dx.doi.org/10.1080/16549716.2018.1434935 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
McMullan, Patrick
Ajay, Vamadevan S.
Srinivas, Ravi
Bhalla, Sandeep
Prabhakaran, Dorairaj
Banerjee, Amitava
Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis
title Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis
title_full Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis
title_fullStr Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis
title_full_unstemmed Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis
title_short Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis
title_sort improving access to medicines via the health impact fund in india: a stakeholder analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844053/
https://www.ncbi.nlm.nih.gov/pubmed/29495950
http://dx.doi.org/10.1080/16549716.2018.1434935
work_keys_str_mv AT mcmullanpatrick improvingaccesstomedicinesviathehealthimpactfundinindiaastakeholderanalysis
AT ajayvamadevans improvingaccesstomedicinesviathehealthimpactfundinindiaastakeholderanalysis
AT srinivasravi improvingaccesstomedicinesviathehealthimpactfundinindiaastakeholderanalysis
AT bhallasandeep improvingaccesstomedicinesviathehealthimpactfundinindiaastakeholderanalysis
AT prabhakarandorairaj improvingaccesstomedicinesviathehealthimpactfundinindiaastakeholderanalysis
AT banerjeeamitava improvingaccesstomedicinesviathehealthimpactfundinindiaastakeholderanalysis